Skip to main content
Peter Merkel, MD, Rheumatology, Philadelphia, PA, Hospital of the University of Pennsylvania

PeterAMerkelMD

Rheumatology Philadelphia, PA

Scleroderma & Related, Vasculitis

Professor, Medicine, Perelman School of Medicine

Dr. Merkel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Merkel's full profile

Already have an account?

  • Office

    3400 Convention Avenue
    University of Pennsylvania
    Philadelphia, PA 19104
    Phone+1 215-614-4401
    Fax+1 215-614-4402
  • Is this information wrong?

Education & Training

  • Harvard School of Public Health
    Harvard School of Public HealthM.P.H., 1995
  • Massachusetts General Hospital
    Massachusetts General HospitalFellowship, Rheumatology, 1992 - 1994
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 1988 - 1991
  • Yale School of Medicine
    Yale School of MedicineClass of 1988
  • Wesleyan University
    Wesleyan UniversityB.A., 1983

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • NJ State Medical License
    NJ State Medical License 2018 - 2025
  • PA State Medical License
    PA State Medical License 1990 - 2024
  • MA State Medical License
    MA State Medical License 1992 - 2019
  • American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

  • Philadelphia Magazine Castle Connolly, 2013-2014
  • America's Top Doctors Castle Connolly, 2006-2011, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features  
    Zachary M Dong, Michael E Wechsler, Praveen Akuthota, Peter A Merkel, Ulrich Specks, Benjamin Raby, Frederic Clayton, The American Journal of Pathology
  • Role of Macrophage Migration Inhibitory Factor in Granulomatosis with Polyangiitis  
    Peter A Merkel, Curry L Koening, Antoine G Sreih, Arthritis & Rheumatology
  • Mapping of the OMERACT core set for ANCA-associated vasculitis to the international classification of function, disability and health  
    Milman N, Boonen A, Merkel PA, Tugwell P, Arthritis Care Res, 1/21/2014
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Lectures

  • Past, Present, and Future of Clinical Trials in Vasculitis. Visiting Professor 
    Fudan Medical University, Shanghai, China - 1/1/2014
  • ANCA-Associated Vasculitis. Visiting Professor 
    University of Pittsburgh, Pittsburgh, PA - 1/1/2014
  • ANCA-Associated Vasculitis: Evaluation and Management 
    1/29/2013
  • Join now to see all

Other

Authored Content

  • Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated VasculitisOctober 2021
  • Arterial Lesions in Giant Cell Arteritis: A Longitudinal StudyMay 2018
  • Arterial Lesions in Giant Cell Arteritis: A Longitudinal StudyMay 2018
  • Arterial Lesions in Giant Cell Arteritis: A Longitudinal StudyMay 2018
  • Join now to see all

Press Mentions

  • Researchers Aim to Use AI to Predict Rare Diseases
    Researchers Aim to Use AI to Predict Rare DiseasesSeptember 21st, 2022
  • Kyverna Therapeutics Names Georg Schett, M.D., and Peter a. Merkel, M.D., MPH, to Scientific Advisory Board
    Kyverna Therapeutics Names Georg Schett, M.D., and Peter a. Merkel, M.D., MPH, to Scientific Advisory BoardAugust 23rd, 2022
  • Two Steps Forward, One Step Back: Hunting for a Game-Changer in Scleroderma
    Two Steps Forward, One Step Back: Hunting for a Game-Changer in SclerodermaMarch 22nd, 2022
  • Join now to see all

Grant Support

  • Conference On Clinical Research For RARE DiseasesNational Institute Of Neurological Disorders And Stroke2010–2011
  • Vasculitis Clinical Research ConsortiumNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2009–2011
  • Plasma Exchange And Glucocorticoids For Treatment Of Anca-Associated VasculitisFood And Drug Administration2009–2011
  • Identification And Validation Of Biomarkers For VasculitisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2009–2010
  • Interpaly Of Thrombosis And Inflammation In VasculitisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2006–2010
  • Vasculitis Clinical Research Network (Vcrn): RARE DiseaseNational Center For Research Resources2004–2008
  • Vasculitis Clinical Research Network (VCRN)National Center For Research Resources2003–2008
  • Vcrc Longitudinal Study For Wegener'S Granulomatosis And Microscopic PolyangitisNational Center For Research Resources2007
  • Vcrc Longitudinal Study For Takayasu'S ArteritisNational Center For Research Resources2007
  • Vcrc Longitudinal Study For Polyarteritis NodosaNational Center For Research Resources2007
  • Vcrc Longitudinal Study For Churg-Strauss SyndromeNational Center For Research Resources2007
  • IL-1 TRAP Administered Sub-Cutaneously In Subjects W Relapsing PolymalgiaNational Center For Research Resources2007
  • Clinical Research For RARE Diseases: Opportunities, Challenges, And SolutionsNational Center For Research Resources2007
  • Rituximab Therapy For Remission And Tolerance In ANCA Associated VasculitisNational Center For Research Resources2006–2007
  • Vasculitis Outcome Measures: Development And ValidationNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2006
  • Study Of Enbrel In The Treatment Of Wegener'S GranulomatosisNational Center For Research Resources2005
  • Development And Validation Of Outcome Measures For Systemic SclerosisNational Center For Research Resources2005
  • Genetic Polymorphisms In Wegener'S GranulomatosisNational Center For Research Resources2004–2005
  • Studies In Scleroderma And Cystic Fibrosis OsteoporosisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2001–2005
  • Study Of Enbrel In Treatment Of Wegener'S GranulomatosisNational Center For Research Resources2004
  • Outcome Measures For Systemic SclerosisNational Center For Research Resources2004
  • Clinical And Biochemical Markers Of Osteoporosis In PTS With Cystic FibrosisNational Center For Research Resources2004
  • Prevalence And Clinical Characteristics Of Cystic Fibrosis ArthropathyNational Center For Research Resources1997–2002
  • Clinical And Biochemical Markers Of Osteoporosis In Cystic FibrosisNational Center For Research Resources1996–2002
  • Study Administering Mycophenolate Mofetil For Active Rheumatoid ArthritisNational Center For Research Resources1999–2001
  • Administering (Mmf RS 61443) PO (1g Bid) In PTS W/ Active Rheumatoid ArthritisNational Center For Research Resources1999–2000
  • Efficacy/Safety Of Mycophenolate Mofetil Immunotherapy In Rheumatoid ArthritisNational Center For Research Resources1998–2000
  • Mmf-Rs 61443 In Patients With Active Rheumatoid ArthritisNational Center For Research Resources1999
  • Recombinant Human Relaxin In PTS W/ Systemic Sclerosis With Diffuse SclerodermaNational Center For Research Resources1997–1999
  • Oral Iloprost &Placebo In Raynaud'S Phenomenon Secondary To Systemic SclerosisNational Center For Research Resources1997
  • Cystic Fibrosis Arthropathy StudyNational Center For Research Resources1996

Professional Memberships

Hospital Affiliations